Survodutide 10mg – GCGR & GLP-1R Dual Agonism in Metabolic Homeostasis Research

Description

What is Survodutide & CAS 1803526-03-3?

Survodutide (developmental code BI 456906) is a pioneering synthetic peptide designed for advanced metabolic research. Identified by the CAS number 1803526-03-3, it is a long-acting glucagon receptor (GCGR) and glucagon-like peptide-1 receptor (GLP-1R) dual agonist. Unlike traditional single-target compounds, Survodutide is engineered to mimic the activity of oxyntomodulin, a naturally occurring hormone that balances energy intake and expenditure.

At 99Purity-Peptide, we provide Survodutide 10mg as a high-purity lyophilized powder. This specialized formulation is optimized for researchers investigating the synergistic effects of simultaneous GLP-1 and glucagon signaling on weight regulation and hepatic health.

Survodutide (CAS 1803526-03-3) Mechanism of Action and Research

The scientific significance of Survodutide lies in its dual-pathway mechanism. By activating the GLP-1 receptor, it suppresses appetite and slows gastric emptying, effectively regulating caloric intake. Simultaneously, its activation of the Glucagon receptor increases energy expenditure by stimulating thermogenesis and improving lipid metabolism in the liver. This “double-action” approach is currently being researched for its potential to achieve more significant weight reduction and liver fat clearance than selective GLP-1 agonists alone.

In recent longitudinal studies, Survodutide has demonstrated promising results in the study of non-alcoholic steatohepatitis (NASH) and obesity-related metabolic disorders. Its stabilized structure allows for a prolonged biological half-life, making it an ideal subject for experiments focusing on the reversal of fatty liver markers and systemic metabolic optimization.

Trending Research Topics & High-Authority Insights:

• Synergistic Energy Expenditure: The role of Glucagon/GLP-1 co-agonism in increasing basal metabolic rate.

• NASH & Hepatic Research: Investigating Survodutide for liver fat reduction and fibrosis reversal.

• Survodutide (BI 456906) for the treatment of obesity – PubMed

Survodutide Specifications

Feature	Specification
Product Name	Survodutide (BI 456906)
Available Strengths	10mg
Physical Appearance	White Lyophilized Powder
Purity	≥ 99% (HPLC/MS Verified)
Molecular Formula	$C_{186}H_{285}N_{49}O_{58}$
Molecular Weight	4135.58 g/mol
CAS Number	1803526-03-3
Verification Method	3rd-Party Lab Tested with COA
Storage Instructions	Store at -20°C (Long-term); 2-8°C after reconstitution

Survodutide Key Features & Benefits

• Dual GCGR/GLP-1R Agonist: Targets two critical metabolic receptors for a comprehensive study of energy balance.

• Advanced Weight Management Research: Optimized for observing the combined effects of appetite suppression and increased energy expenditure.

• Elite Purity Formulation: Synthesized at 99%+ purity to ensure experimental reliability and accurate laboratory data.

• Vacuum-Sealed Lyophilization: Professionally freeze-dried to maintain molecular stability during global shipping and storage.

• Verified Chemical Profile: Each batch is confirmed via HPLC and Mass Spectrometry to guarantee exact amino acid sequence and potency.

Survodutide FAQ

How does Survodutide differ from standard GLP-1 peptides?

Standard GLP-1 peptides primarily focus on appetite suppression. Survodutide adds a second mechanism—Glucagon receptor activation—which is researched for its ability to actually burn more calories by increasing the body’s energy expenditure.

What research applications is Survodutide 10mg used for?

Survodutide is primarily utilized in research involving obesity, type 2 diabetes, and liver diseases like NASH (MASH). Researchers study its dual-action profile to observe how it handles hepatic fat clearance.

How should I store the Survodutide lyophilized powder?

For long-term stability, keep the vial at -20°C. Once reconstituted with bacteriostatic water, the solution should be refrigerated at 2-8°C and utilized within 14-21 days for maximum research efficacy.

Is a Certificate of Analysis (COA) provided with Survodutide?

Yes. 99Purity-Peptide provides a 3rd-party COA with every order to verify that the purity and identity of the Survodutide meet strict 99%+ laboratory standards.

Why Buy Survodutide online from 99Purity-Peptide?

• Pioneering Biotech Consistency: We offer the latest metabolic research compounds with guaranteed batch-to-batch stability, ensuring your data is never compromised.

• Discreet & Secure Global Logistics: Your research privacy is a priority. All orders are sent in unbranded, secure packaging with tracked shipping to the USA, UK, and Europe.

• Professional Grade Reliability: As a specialized supplier, we offer 1-2 business day dispatch and expert technical support for all your high-demand research peptides.

• Verified Quality Guarantee: Every purchase is backed by HPLC/MS verification, ensuring you receive the highest purity materials for your metabolic and liver research projects.

Payment Support & Logistics

• Secure Payment Options: We support multiple secure gateways, including Credit Cards, Cryptocurrency (USDT, USDC), PayPal, and Bank Transfers.

• Global Shipping: Fast, tracked delivery available to the United States, United Kingdom, and Europe.

• Processing Time: All orders are professionally handled and dispatched within 1-2 business days after payment confirmation.

Regulatory Disclaimer

99Purity-Peptide is a chemical supplier. We are not a compounding pharmacy or an outsourcing facility as defined under Sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act (FD&C Act). All products are strictly for research, laboratory, or analytical use only and are NOT for human consumption.

References & Academic Links

• Le Roux, C. W., et al. (2023). “Survodutide (BI 456906) for the treatment of obesity: a phase 2 randomised, double-blind, placebo-controlled, dose-finding study.” The Lancet Diabetes & Endocrinology.

• Zimmermann, T., et al. (2022). “BI 456906: A novel glucagon/GLP-1 receptor dual agonist for the treatment of obesity and NASH.” Journal of Hepatology.